BlackRock Fund Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

BlackRock Fund Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.37M	Sell	138,018 -70,859	-34%	-$2.02M	﹤0.01%	3052
2016 Q3	$7.92M	Buy	208,877 +11,798	+6%	+$371K	﹤0.01%	2596
2016 Q2	$5.87M	Buy	197,079 +107,176	+119%	+$3.77M	﹤0.01%	2701
2016 Q1	$2.66M	Buy	89,903 +8,248	+10%	+$247K	﹤0.01%	2994
2015 Q4	$3.7M	Buy	81,655 +77,468	+1,850%	+$3.38M	﹤0.01%	2980
2015 Q3	$157K	Buy	+4,187	New	+$192K	﹤0.01%	3572

Other funds holding RCKT

RCP

Rho Capital Partners New York $20.4M AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's RCKT Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 34% in Q4 2016, selling an estimated $2.02M and leaving 138,018 shares worth $3.37M. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

BlackRock Fund Advisors first reported a position in RCKT in Q3 2015 and has held it in 6 quarters since. The position peaked at $7.92M in Q3 2016. 82 funds tracked by Wall St. Rank hold RCKT as of Q4 2016.

BlackRock Fund Advisors held 138,018 shares of Rocket Pharmaceuticals worth $3.37M as of Q4 2016.
BlackRock Fund Advisors sold 70,859 Rocket Pharmaceuticals shares in Q4 2016, an estimated $2.02M.
Rocket Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3052 holding.
BlackRock Fund Advisors first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 6 quarters since.
BlackRock Fund Advisors's Rocket Pharmaceuticals position peaked at $7.92M in Q3 2016.
82 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.